Web Version

Anti-COVID-19 Compound Library

Our partner TargetMol, a drug screening expert, has generated a compound library by carefully selecting 2448 compounds that have been demonstrated to have anti-coronavirus activity.

  • Unique collection of 2448 compounds with anti-SARS-CoV-2 activity
  • Includes Remdesivir, Lopinavir/Ritonavir, Chloroquine diphosphate
  • Detailed information like structure, target and biological activity
  • Validated by NMR and HPLC/LCMS to ensure high purity and quality

Anti-COVID-19 Compound Libraries (CADD)

Applying Computer-Aided Drug Design (CADD), TargetMol has developed Anti-COVID-19 Compound Libraries targeting individual SARS-CoV-2 key proteins like Spike-RBD, ACE2, Mpro (3CLpro), PLpro, Nsp16, X domain and RdRp (Nsp12).


Antiviral Agents

Based on virtual screening results and combined with the recent clinical reports, TargetMol has obtained some promising SARS-CoV-2 drug candidates, including Remdesivir, Darunavir, Camostat mesilate, Baricitinib, Favipiravir, Ribavirin, Chloroquine diphosphate and Nitazoxanide.


SARS-CoV-2 Research Reagents Overview

BioCat GmbH

Im Neuenheimer Feld 584
D-69120 Heidelberg
Tel:  +49 (0) 6221 7141516
Fax: +49 (0) 6221 7141529
Email: info@biocat.com
Web: https://www.biocat.com